Sufugolix

DB06494ExperimentalSmall molecule

Investigated for use/treatment in endometriosis and uterine fibroids.

Mechanism: Endometriosis is a painful, fertility threatening condition that is a result of tissue similar to that found in the womb lining growing elsewhere in the pelvis. The condition is sex hormone dependent, with gonadotropin releasing hormone (GnRH), a hypothalamic decapeptide amide that plays an important part in the regulation of reproductive processes, being implicated. TAK-013 behaves as an insurmountable antagonist at the human receptor (hGnRHR). It suppresses gonadotropin release.
Curator reviewed
Primary indication: Investigated for use/treatment in endometriosis and uterine fibroids.Curator reviewed
Formula / weight: C₃₆H₃₁F₂N₅O₄S · 667.73 g/mol (avg)
Code names: TAK-013

Resolves to

Compound

Structure

InChIKeyUCQSBGOFELXYIN-UHFFFAOYSA-NSMILESCONC(=O)NC1=CC=C(C=C1)C1=C(CN(C)CC2=CC=CC=C2)C2=C(S1)N(CC1=C(F)C=CC=C1F)C(=O)N(C2=O)C1=CC=CC=C1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Sufugolix, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.